Concepedia

Keiji Imai

KI

8

Publications

458

Citations

8

H-Index

2005

Active since

Affiliations

Astellas Pharma (Japan)(Current)

Toho University

Pfizer (United States)

Okayama University

Pfizer (Japan)

Keiji Imai is an author at Astellas Pharma (Japan) specializing in pharmacology, medicine, and biomedical engineering.

Top concepts

Publications per year

2005–2017

8

Publications

8

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto et al. · European Journal of Cancer · 2011 · 123 citations

, , +7

Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): In vivo evaluation

Nobuyuki Tanaka, Keiji Imai, Kazuto Okimoto et al. · Journal of Controlled Release · 2006 · 93 citations

, , +6

Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine

Nobuyuki Tanaka, Keiji Imai, Kazuto Okimoto et al. · Journal of Controlled Release · 2005 · 76 citations

, , +7

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami et al. · Investigational New Drugs · 2012 · 63 citations · Full text

Process analytical technology applied for end-point detection of pharmaceutical blending by combining two calibration-free methods: Simultaneously monitoring specific near-infrared peak intensity and moving block standard deviation

Wataru Momose, Keiji Imai, Shoji Yokota et al. · Powder Technology · 2011 · 43 citations

, , +11

Rows per page

1–5 of 8